-

New Non-Hazardous Viral Inactivation Medium Supports Safe Collection and Transport of SARS-CoV-2

Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing

BASINGSTOKE, England--(BUSINESS WIRE)--A new viral transport medium that enables collection and rapid inactivation of the SARS-CoV-2 virus, and stabilizes viral RNA at ambient temperature for transportation and use in in vitro diagnostic testing procedures, is now available in Europe.

Thermo Fisher Scientific developed the InhibiSURE Viral Inactivation Medium formula to be non-hazardous. Other inactivation media typically rely on a formulation that is potentially hazardous to inactivate viruses. Many contain a guanidine-based chemical that, if mixed with bleach or strong acids, could release toxic cyanide gas. The use of inactivation medium also removes the need for further inactivation steps, increasing laboratory throughput.

This single-use device, for professional use only, can be used for sampling patients that are suspected of being infected with SARS-CoV-2 or sampling individuals for population screening for SARS-CoV-2.

“As testing demands continue to change dynamically throughout this pandemic, we remain committed to keeping laboratorians safe and protected during the testing process,” said Duncan Porter, general manager, sample collection and transport for Thermo Fisher’s microbiology business. The InhibiSURE Viral Inactivation Medium enables us to support a safe and efficient sample collection and transport process by rapidly inactivating the SARS-CoV-2 virus using a non-hazardous formulation. To broaden the scope of those capabilities, we’ve prioritized the expansion of the range of viruses, as well as the ability to do at-home collection as future developments.”

InhibiSURE Viral Inactivation Medium:

  • Helps keep staff safe, inactivating SARS-CoV-2 within 30 minutes of sampling with a non-hazardous formula that does not contain any products that may react with bleach
  • Provides a convenient, leakproof, format that can be used with unprocessed nasal swabs, nasopharyngeal swabs or throat swabs on automation preparation racks and decappers
  • Enhances simplicity by removing the need for de-activation steps, and is suitable for use with bead and column-based PCR systems

InhibiSURE Viral Inactivation Medium is now commercially available from Thermo Fisher Scientific in Europe, with plans for launch in other regions pending relevant regulatory approvals. For more information, visit thermofisher.com/viraltesting.

Product is CE marked but not 510(k)-cleared and not available for sale in the U.S. Availability of product in each country depends on local regulatory marketing authorization status.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Carlene Graham
Global Marketing Communications Manager
Microbiology
Thermo Fisher Scientific
Phone +1 216.704.3479
carlene.graham@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)


Contacts

Carlene Graham
Global Marketing Communications Manager
Microbiology
Thermo Fisher Scientific
Phone +1 216.704.3479
carlene.graham@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Expands Gibco™ Bacto™ Portfolio with Next-Generation, Chemically Defined Media to Boost E. coli Biomanufacturing Productivity

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Gibco™ Bacto™ CD Supreme FPM Plus and Gibco™ Bacto™ CD Supreme Feed (2X), two next-generation chemically-defined formulations that expand the Gibco™ Bacto™ CD portfolio to enhance and simplify plasmid DNA and recombinant protein production using Escherichia coli (E. coli). As demand for plasmid DNA continues to surge to support expanding gene therapy and mRNA vaccin...

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...
Back to Newsroom